Cite
APA Citation
Samaniego, F., McLaughlin, P., Neelapu, S. S., Feng, L., Fanale, M., Nastoupil, L., Rodriguez, M. A., Pro, B., Taylor, E., Hagemeister, F. B., & Fowler, N. (2021). initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leukemia & lymphoma, 62(1), 58–67. http://access.bl.uk/ark:/81055/vdc_100118922885.0x000039